The counter opened at Rs 625.1 and touched an intraday high and low of Rs 639.75 and Rs 623.1, respectively, in the session so far. The stock of Aurobindo Pharma Ltd. quoted a 52-week high of Rs 1063.75 and a 52-week low of Rs 620.55.
As per BSE, the total market cap of the Aurobindo Pharma Ltd. stood at Rs 37415.11 crore at the time of writing this report.
Key Financials
The company reported consolidated sales of Rs 6038.5 crore for the quarter ended 30-Sep-2021, up 4.41 per cent from previous quarter’s Rs 5783.29 crore and up 7.63 per cent from the year-ago quarter’s Rs 6537.19 crore.
The net profit for latest quarter stood at Rs 696.99 crore, down 13.55 per cent from the corresponding quarter last year.
Shareholding pattern
As of 30-Sep-2021, DIIs held 9.28 per cent stake in the company, while foreign institutional investors held 21.71 per cent and the promoters 48.76 per cent.
Valuation ratio
According to BSE data, the stock traded at a price-to-earnings multiple of 7.17 and a price-to-book ratio of 2.36. A higher P/E ratio shows investors are willing to pay a higher price because of better future growth expectations. Price-to-book value indicates the inherent value of a company and is the measure of the price that investors are ready to pay even for no growth in the business.
Aurobindo Pharma Ltd. belongs to the Pharma – Indian industry.
